Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-021-02767-7
Abstract: Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. RAS mutant… read more here.
Keywords: ras mutant; mutant clones; solid liquid; liquid biopsies ... See more keywords
Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.009
Abstract: Abstract Background MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in preclinical RAS mutant cancer models. BCL-XL is an anti-apoptotic BCL2 family protein… read more here.
Keywords: bcl mek; treatment; inhibition; ras mutant ... See more keywords
Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz394.020
Abstract: Abstract Background To assess the effects of bevacizumab plus chemotherapy as first-line treatment for RAS mutant unresectable colorectal liver metastases (CLMs). Methods From June 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases… read more here.
Keywords: chemotherapy; mutant unresectable; liver; ras mutant ... See more keywords
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Sign Up to like & getrecommendations! Published in 2020 at "Science Signaling"
DOI: 10.1126/scisignal.aay6013
Abstract: New signaling insights level the playing field against the notoriously “undruggable” protein RAS. Oncogenic RAS proteins, which are mutated in approximately 24% of all human cancers, have earned a well-deserved reputation as being “undruggable.” However,… read more here.
Keywords: ras proteins; ras wanted; ras mutant; wanted dead ... See more keywords
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-22-0198
Abstract: This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies biomarkers of response, and uncovers targetable mechanisms of resistance. read more here.
Keywords: ras mutant; mek cdk4; mutant colorectal; colorectal cancer ... See more keywords
Abstract B129: Preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-b129
Abstract: Background: Cancer cells activate autophagy, a catabolic process to resupply nutrients and recycle damaged organelles, in order to survive stresses such as limited nutrients and hypoxia, or chemotherapy treatments. RAS mutant cancers, in particular, have… read more here.
Keywords: autophagy; cancer; ras mutant; dcc 3116 ... See more keywords
Abstract 5160: Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-5160
Abstract: REDX05358 has been identified as a novel, highly selective and potent next generation pan RAF inhibitor with improved therapeutic potential and predicted safety profile. Aberrant signalling via the MAPK pathway is commonly seen in cancer.… read more here.
Keywords: braf; ras mutant; braf ras; raf inhibitor ... See more keywords
Abstract 6415: RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-6415
Abstract: K-RAS mutation represents one of the most frequent genetic alterations in cancers. Monotherapy approaches targeting RAS downstream effectors such as MEK and ERK have had limited clinical success in patients with K-RAS-mutated cancers. The reduced… read more here.
Keywords: inhibitor; mek inhibitor; raf dimer; dimer inhibitor ... See more keywords
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/1538-7445.am2022-2010
Abstract: Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. Disease progression on single agent MEK inhibitors is common, however, and combination therapies are typically required… read more here.
Keywords: ras mutant; inhibition; mek inhibition; mek ... See more keywords
Abstract 3413: RTK/SHP2 dependency and feedback adaptation to MEK inhibition defines sensitivity of RAS-mutant proteins to SHP2 inhibitor-based therapies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3413
Abstract: Activating RAS mutations constitute the majority of recurrent mutations found in MAPK-driven human tumors. However, RAS mutants have long been considered undruggable, and therefore efforts have been predominantly focused on targeting downstream MAPK signaling. We… read more here.
Keywords: ras mutant; inhibition; rtk shp2; shp2i ... See more keywords
Abstract A010: Using oncogenic pathway agonism to sensitize RAS-mutant cancers to immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a010
Abstract: Overall, some 30% of human cancers are driven by mutant RAS proteins, which have proven relatively difficult to target. While immunotherapy is effective for NRAS-mutant melanoma, no options exist for resistant disease, and mutant KRAS-driven… read more here.
Keywords: oncogenic pathway; ras mutant; sensitize ras; pathway agonism ... See more keywords